Table 1. Expression of IL-21R and... | American Society of Hematology

Table 1.

Expression of IL-21R and prognostic markers of the CLL patients studied

Patient no.	IL-21R, %	CD38, %	ZAP70, %	VH mutations, %
1	34	12	32	9.7
2	30	6	89	0.0
3	33	9	95	9.5
4	13	37	90	ND
5	26	14	35	5.3
6	10	53	24	1.4
7	10	96	88	0.0
8	6	34	46	9.7
9	10	30	55	2.7
10	15	47	99	0.7
11	14	69	19	9.5
12	16	67	64	0.0
13	29	2	1	7.6
14	19	5	25	3.8
15	34	6	21	5.9
16	18	3	5	5.6
17	48	6	55	3.2
18	35	6	52	0.0
19	49	3	15	0.0
20	47	4	67	4.1
21	2	74	65	0.0
22	28	52	68	0.0
23	40	7	16	7.0
24	20	1	28	10.4
25	25	1	25	8.1
26	24	87	70	0.0
27	16	10	15	ND
28	30	1	28	8.3
29	13	49	78	0.0
30	40	52	48	0.0
31	18	1	16	9.8
32	8	31	6	9.1
33	13	85	39	1.0

Patient no.	IL-21R, %	CD38, %	ZAP70, %	VH mutations, %
1	34	12	32	9.7
2	30	6	89	0.0
3	33	9	95	9.5
4	13	37	90	ND
5	26	14	35	5.3
6	10	53	24	1.4
7	10	96	88	0.0
8	6	34	46	9.7
9	10	30	55	2.7
10	15	47	99	0.7
11	14	69	19	9.5
12	16	67	64	0.0
13	29	2	1	7.6
14	19	5	25	3.8
15	34	6	21	5.9
16	18	3	5	5.6
17	48	6	55	3.2
18	35	6	52	0.0
19	49	3	15	0.0
20	47	4	67	4.1
21	2	74	65	0.0
22	28	52	68	0.0
23	40	7	16	7.0
24	20	1	28	10.4
25	25	1	25	8.1
26	24	87	70	0.0
27	16	10	15	ND
28	30	1	28	8.3
29	13	49	78	0.0
30	40	52	48	0.0
31	18	1	16	9.8
32	8	31	6	9.1
33	13	85	39	1.0

ND indicates not determined.

IL-21R expression was assessed by immunoflurescence with a PE-conjugated anti–IL-21R mAb. The percentage of positive cells is shown for each case. ZAP-70 and CD38 expression was evaluated as described in “Materials and methods.”

P < .001, IL-21R versus CD38; P = .6, IL-21R versus ZAP-70; and P = .9, IL-21R versus IgVH mutations.

View Large

This Feature Is Available To Subscribers Only